RxDoctor Payments Data

Daniel Kim, MD

Internal Medicine · Santa Cruz, CANPI 1124008313

Payments from drug & device makers

$5,493in general payments, 2019–2025

Across 61 payments — averaging $90.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$548
  • Biocryst US Sales Co., LLC$384
  • Sanofi$367
  • Blueprint Medicines Corporation$271
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,43299%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,493 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$369,197
Medicare patients
300
Services billed
18,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab59$278,574
Dupixent PenDupilumab44$180,611
XolairOmalizumab21$61,457
NucalaMepolizumab13$49,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,756
Breo ElliptaFluticasone/Vilanterol23$18,285
AlvescoCiclesonide17$13,755
Epinephrine56$11,479
Spiriva RespimatTiotropium Bromide12$7,845
Advair HfaFluticasone Propion/Salmeterol12$6,893
Qvar RedihalerBeclomethasone Dipropionate16$6,586
Azelastine-FluticasoneAzelastine/Fluticasone45$6,284
SymbicortBudesonide/Formoterol Fumarate22$6,205
Azelastine Hcl135$5,543
QnaslBeclomethasone Dipropionate16$4,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,133$109,00589 claims
Genentech, Inc.Xolair$150$61,45721 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl$121$11,28432 claims
AstraZenecaSymbicort$1,284$6,20522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →